EU draft opinion on ACTA still flawed, says MSF, urging member states not to sign
The European Union Parliament Committee on Development released its draft opinion this week on the Anti-Counterfeiting Trade Agreement (ACTA), which will be voted on next Monday (May 14). Medecins Sans Frontieres (MSF) believes that this draft opinion is still fundamentally flawed and should not be accepted or signed by the EU and its member states in its current form.
The ACTA is a treaty that seeks to establish standards for intellectual property rights enforcement. Protests were held in several European cities earlier this year over concerns on the impact of ACTA, mostly on internet freedom, but MSF has raised serious concerns over the impact on access to medicines.
MSF views on the EP Committee on Development's draft opinion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze